TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated DiseasesJanuary 9, 2023
TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated DiseasesMarch 8, 2022
TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and InflammationJanuary 6, 2022
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory DiseasesJune 22, 2021
Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBioJanuary 9, 2023 – Endpoints News
Jurassic Ambitions: TRexBio Targets Tregs with Janssen CollaborationJanuary 10, 2022 – Genetic Engineering & Biotechnology News
Biotech TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma fundingJun 22, 2021 – Fierce Biotch
Big Pharma backers jump on board ‘Treg’ cartographer’s lead round with up to six candidates in the pipeJune 22, 2021 – Endpoints News